NDAORALTABLET
Approved
Apr 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERCODAN-DEMI is an oral tablet combining aspirin with oxycodone (as hydrochloride and terephthalate salts) for pain management. It is a fixed-dose opioid-analgesic combination indicated for moderate pain relief. The aspirin provides anti-inflammatory and analgesic activity while oxycodone delivers opioid analgesia.
LOE Approaching
LOE-approaching status indicates declining market position; commercial team focus is likely on managed decline and cost containment rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PERCODAN-DEMI offers limited career growth opportunity given its LOE-approaching lifecycle and zero linked job openings. Roles are concentrated in regulatory maintenance, compliance, and managed decline rather than innovation or market expansion. Career development on this product is typically a mature-stage responsibility for mid-to-senior professionals managing legacy portfolios.
Regulatory Affairs Specialist
Worked on PERCODAN-DEMI at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.